Nattokinase Dosage for Blood Pressure: Evidence Guide

You've read that nattokinase can help lower blood pressure. But when you try to figure out how much to take, the answers get confusing fast. Some sources say 2,000 FU. Others mention 10,800 FU. And if you're already on blood pressure medication, the safety questions multiply.

The confusion isn't your fault. Nattokinase dosage research spans decades, multiple countries, and wildly different study designs. Some trials tested it in people with borderline hypertension, others in patients with full cardiovascular disease. The doses, durations, and outcomes vary enough to make any straightforward answer feel incomplete.

We reviewed the clinical trial evidence — including a systematic review of six randomized controlled trials, a landmark study with over 1,000 participants, and Japanese research that most English-language guides overlook — to give you a clear, evidence-based answer on nattokinase dosage for high blood pressure. This guide covers what actually works, what the limitations are, and what you should know if you're taking blood pressure medication.

What Is Nattokinase?

Nattokinase is a fibrinolytic enzyme produced during the fermentation of soybeans into natto, a traditional Japanese food with centuries of history. It was first identified in 1987 by Dr. Hiroyuki Sumi at the University of Chicago Medical School, who discovered its remarkable ability to dissolve fibrin — the protein that forms blood clots ^[4].

Structurally, nattokinase is a serine protease consisting of 275 amino acids with a molecular weight of approximately 27.7 kDa ^[5]. What makes it unusual among dietary supplements is its well-characterized mechanism of action — it doesn't just "support" cardiovascular health in vague terms. It acts through specific, measurable biochemical pathways.

Understanding FU (Fibrinolytic Units)

When shopping for nattokinase supplements, you'll encounter FU (Fibrinolytic Units) — the standardized measure of the enzyme's fibrin-dissolving activity. This is the number that matters for dosing, not milligrams alone. 2,000 FU is approximately equivalent to 100 mg of nattokinase extract, though this ratio varies by manufacturer and extraction method View source.

Think of FU as a measure of potency. Two products could both contain 100 mg of nattokinase extract, but if one delivers 2,000 FU and the other delivers 4,000 FU, the second product has twice the fibrinolytic activity per dose.

How Nattokinase Affects Blood Pressure

Nattokinase works through multiple mechanisms that collectively influence blood pressure — and understanding these helps explain both its potential benefits and its interaction risks with medications.

Fibrinolytic Activity

The primary mechanism is direct fibrinolysis — nattokinase breaks down fibrin in the blood. This reduces blood viscosity and improves circulation. Research shows that D-dimer levels (a marker of fibrin breakdown) increase measurably within 6-8 hours of ingestion, confirming active fibrinolysis in the body ^[16].

ACE Inhibition

Perhaps more relevant to blood pressure specifically, nattokinase and peptides derived from natto have been shown to inhibit angiotensin-converting enzyme (ACE) in a dose-dependent manner ^[14]. This is the same mechanism used by prescription ACE inhibitors like lisinopril and enalapril — one of the most common classes of blood pressure medication. Japanese researchers have identified specific ACE-inhibitory peptides from natto that contribute to this effect ^[22].

Renin Activity Reduction

A well-designed clinical trial found that nattokinase supplementation significantly decreased plasma renin activity (p<0.05), suggesting it may also act directly on the renin-angiotensin system — the hormonal pathway that regulates blood pressure ^[1].

Antithrombotic Effects

Nattokinase also reduces platelet aggregation and has been shown to decrease von Willebrand factor (a cardiovascular risk marker) by approximately 15% compared to placebo in a multicenter trial ^[2]. While this is more relevant to clot prevention than blood pressure per se, reduced blood viscosity contributes to overall cardiovascular benefit.

Evidence-Based Dosage Recommendations

Standard Dosage: 2,000 FU (100 mg) Daily

The most studied and recommended dose for blood pressure support is 2,000 FU per day, taken as a single dose. This is the dosage used in the majority of clinical trials that showed statistically significant blood pressure reductions ^[3].

At this dose, a meta-analysis of six randomized controlled trials found:

• Systolic blood pressure reduction: -3.45 mmHg (95% CI: -4.37 to -2.18, p<0.00001)
• Diastolic blood pressure reduction: -2.32 mmHg (95% CI: -2.72 to -1.92, p<0.00001)

These numbers may seem modest, but at a population level, a 3-5 mmHg reduction in systolic blood pressure is associated with meaningful decreases in cardiovascular event risk.

Higher Dosages: 4,000-10,800 FU

Emerging research has explored higher doses, primarily for atherosclerosis and lipid management rather than blood pressure as a primary endpoint:

The study with 1,062 participants using 10,800 FU/day for 12 months found effective plaque reduction and lipid improvement with no serious side effects reported ^[7]. However, this dose has not been specifically studied for blood pressure as a primary endpoint, and should only be considered under medical supervision.

A review published in Nutrients noted that doses up to 10,000 FU/day have shown no serious side effects in available data ^[10]. That said, higher doses also mean higher interaction risk with blood-thinning and blood-pressure-lowering medications.

Our Assessment

For blood pressure support specifically, 2,000-4,000 FU per day represents the evidence-supported range. Start with 2,000 FU and consult your healthcare provider before considering higher doses — especially if you take any cardiovascular medications.

Clinical Trial Evidence for Blood Pressure

What the Meta-Analysis Shows: Moderate Evidence

The most comprehensive analysis of nattokinase for blood pressure comes from a systematic review and meta-analysis published in Reviews in Cardiovascular Medicine. This analysis pooled data from six randomized controlled trials involving approximately 607 participants ^[3].

Key findings:

• Nattokinase significantly reduced both systolic and diastolic blood pressure compared to placebo
• The effects were statistically robust (p<0.00001 for both measures)
• Benefits were more pronounced in hypertensive populations than in normotensive individuals
• A comparative review published in Biomolecules confirmed significant blood pressure effects across studies ^[11]

The Strongest Positive Trial

The most frequently cited positive trial involved 73 participants with pre-hypertension or Stage 1 hypertension who received either 2,000 FU of nattokinase or placebo daily for 8 weeks. Results showed a net systolic blood pressure reduction of -5.55 mmHg (95% CI: -10.5 to -0.57, p<0.05) and diastolic reduction of -2.84 mmHg (95% CI: -5.33 to -0.33, p<0.05). Notably, plasma renin activity also decreased significantly ^[1].

The Important Negative Finding

Transparency requires acknowledging the Nattokinase Atherothrombotic Prevention Study (NAPS) — the largest and longest randomized controlled trial of nattokinase. This study followed 265 participants taking 2,000 FU daily for a median of 3 years. It found no significant difference in blood pressure between nattokinase and placebo groups ^[6].

This is an important result. It suggests that the blood pressure reductions seen in shorter 8-week trials may not persist long-term, or that the effects may be population-specific. The NAPS trial studied participants with subclinical atherosclerosis, while the positive trials focused on people with elevated blood pressure.

What This Means for You

The evidence for nattokinase and blood pressure is moderate — not definitive. Short-term trials (8 weeks) consistently show modest reductions, but the longest trial did not confirm lasting effects. Nattokinase shows more promise for people with borderline or mildly elevated blood pressure than for those with established hypertension.

This is not a substitute for blood pressure medication, and it should not be marketed or perceived as one. It may, however, be a reasonable complementary approach for individuals with borderline readings, under medical guidance.

How Long Until You See Results?

Based on the clinical evidence, expect a minimum of 8 weeks before measurable blood pressure changes occur. This is the standard trial duration across the positive studies, and the point at which significant effects were measured ^[1][3].

That said, nattokinase begins working at a biochemical level much sooner. Fibrinolytic activity is detectable within 6-8 hours of ingestion, as evidenced by increased D-dimer levels ^[16]. But biochemical activity and measurable blood pressure changes are different things — the circulatory benefits take time to accumulate.

Factors that may influence your timeline:

• Baseline blood pressure — people with higher starting readings tend to see more noticeable reductions
• Consistency — daily intake is essential; intermittent use has not been studied
• Lifestyle factors — diet, exercise, stress management, and sleep all interact with blood pressure
• Individual variation — some research suggests stronger effects in males than females

A realistic expectation: If nattokinase works for you, you may notice modest improvements in home blood pressure readings after 2-3 months of consistent daily use. If you see no change after 3 months, the benefit for your individual situation may be limited.

Safety Considerations

Overall Safety Profile

Clinical trials consistently report nattokinase as well-tolerated. A meta-analysis of randomized controlled trials noted that "no notable adverse events were reported in all studies" at standard doses ^[3]. A real-world study of 153 patients with vascular disease taking nattokinase alongside anticoagulant medications for 30 days found no adverse reactions, interactions, or new vascular events ^[8].

A comprehensive toxicological assessment confirmed nattokinase is non-mutagenic and non-clastogenic, with no subchronic toxicity observed in 90-day animal studies at doses far exceeding human supplementation levels ^[9].

Drug Interactions — Critical Information

This is the most important safety consideration for people researching nattokinase dosage for high blood pressure:

Anticoagulants (warfarin, heparin, enoxaparin, fondaparinux): Nattokinase has inherent fibrinolytic and antithrombotic activity. Taking it alongside blood-thinning medications creates a theoretical risk of excessive bleeding. While one real-world study found no interactions in 153 patients, close INR monitoring is strongly recommended ^[8][21].

Antiplatelet drugs (aspirin, clopidogrel): Similar theoretical concern — additive effects on platelet function could increase bleeding risk. No clinical interactions have been documented, but caution is warranted ^[21].

Antihypertensive medications: Since nattokinase can lower blood pressure by approximately 3-5 mmHg, combining it with blood pressure medication could potentially cause hypotension (excessively low blood pressure). If you take any blood pressure medication, consult your doctor before adding nattokinase. Monitor your blood pressure at home and watch for symptoms like dizziness, lightheadedness, or fatigue.

Who Should Avoid Nattokinase

• People with active bleeding disorders — nattokinase's fibrinolytic activity could worsen bleeding
• Pre-surgical patients — discontinue nattokinase at least 2 weeks before any planned surgery
• Soy allergy — nattokinase is derived from soy fermentation
• Pregnant or nursing women — no clinical safety data exists for these populations

Realistic Expectations

Nattokinase is not a replacement for blood pressure medication. The evidence shows modest reductions (3-5 mmHg systolic) in specific populations, and the longest trial found no significant effect. It may be a reasonable complementary approach for borderline blood pressure under medical supervision — but it does not treat hypertension.

What Most Guides Miss About Nattokinase and Blood Pressure

JNKA Certification: The Quality Standard That Matters

The Japan Nattokinase Association (JNKA) maintains a certification program that ensures nattokinase supplements meet standardized fibrinolytic activity requirements ^[18]. This is significant because FU (Fibrinolytic Units) measurement can vary between manufacturers. JNKA-certified products guarantee that the FU count on the label reflects actual enzymatic activity — something that isn't standardized in many international products.

Why this matters: When a clinical trial uses 2,000 FU of nattokinase, it relies on accurate FU measurement. If the supplement you buy doesn't actually deliver 2,000 FU of activity, you're not replicating the study conditions. JNKA certification bridges this gap.

Japan's Functional Food Framework Targets Your Exact Situation

In Japan, nattokinase supplements are registered as 機能性表示食品 (Foods with Function Claims) with the Consumer Affairs Agency (消費者庁) ^[20]. Companies like Kobayashi Pharmaceutical have registered claims that nattokinase "improves peripheral blood flow, supporting blood pressure reduction in those with elevated levels" ^[19].

The key detail: Japanese functional food claims specifically target people with "高めの血圧" (borderline high blood pressure) — systolic 130-139 mmHg or diastolic 85-89 mmHg. This aligns precisely with the clinical trial populations where nattokinase showed the most promising results.

Why this matters: Japan's regulatory framework has already identified the population most likely to benefit — people with borderline readings, not those with established hypertension. This nuance is absent from most English-language nattokinase guides.

Japanese Research on ACE-Inhibitory Peptides Goes Deeper

While international research focuses primarily on nattokinase's fibrinolytic activity, Japanese researchers have identified specific ACE-inhibitory peptides produced during natto fermentation that contribute to blood pressure reduction through an entirely separate mechanism ^[14].

Studies published on J-STAGE have demonstrated that these peptides inhibit angiotensin-converting enzyme in a dose-dependent manner, producing blood pressure reduction in spontaneously hypertensive rats. Japanese research on nattokinase and blood pressure is thus broader than the fibrinolysis story alone — it encompasses enzymatic peptides that act on the renin-angiotensin system ^[15].

Why this matters: The dual mechanism (fibrinolysis + ACE inhibition) may explain why nattokinase has blood pressure effects that extend beyond what fibrinolysis alone would predict — and why the dose-response relationship may not be linear.

Manufacturing Standards Differ More Than You'd Expect

Japanese nattokinase manufacturers like Japan Bio Science Laboratory (JBSL) use strict quality protocols that include verified FU testing, natto bacteria purity standards, and clinical backing for their products ^[23]. International products often lack equivalent activity testing or standardized fermentation processes, which can result in inconsistent FU delivery between batches.

Why this matters: Consistency matters when you're taking a supplement daily for months. Japanese-manufactured nattokinase products, particularly those with JNKA certification, offer a level of quality assurance that directly supports the dosage recommendations from clinical research.

Our Recommendations

Japanese Nattokinase 4000

Why We Selected This: This supplement delivers 4,000 FU per serving — above the standard clinical trial dose of 2,000 FU, allowing flexibility in dosing. It's manufactured in Japan with quality standards aligned to JNKA certification requirements. We selected it for customers looking for a higher-potency nattokinase option for cardiovascular support.

The 4,000 FU dosage is particularly relevant for those who want to match or exceed the clinical trial dose while maintaining the quality assurance of Japanese manufacturing.

View Japanese Nattokinase 4000 →

Nattokinase EX

Why We Selected This: A Japanese-formulated nattokinase supplement designed specifically for cardiovascular support. The "EX" formulation is designed for daily use, making it a practical choice for consistent supplementation as the clinical evidence recommends.

View Nattokinase EX →

Noguchi Nattokinase HQ

Why We Selected This: From the Noguchi brand — a name with heritage in Japanese health supplementation. This premium formulation offers a high-quality nattokinase option for those who prioritize brand reputation alongside clinical efficacy.

View Noguchi Nattokinase HQ →

Product Comparison

Conclusion

The evidence for nattokinase dosage for high blood pressure points to a clear starting point: 2,000 FU (approximately 100 mg) per day for at least 8 weeks. A meta-analysis of randomized controlled trials supports modest but statistically significant reductions in both systolic and diastolic blood pressure, and the safety profile is reassuring at this dose.

However, honesty demands acknowledging the limitations. The longest clinical trial (3 years) did not confirm lasting blood pressure effects, most positive trials are small, and nattokinase is not a substitute for prescribed medication. It shows the most promise for people with borderline or mildly elevated blood pressure — precisely the population that Japan's functional food regulatory framework targets.

If you're considering nattokinase, look for Japanese-manufactured products with JNKA certification to ensure consistent FU activity. And if you take any cardiovascular medications, talk to your doctor before starting. Blood pressure management is too important for guesswork.

This article is for informational purposes only and does not constitute medical advice. Consult a healthcare professional before starting any new health regimen, especially if you have existing health conditions or take medications. Statements about dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.